Association between use of cardiovascular medicines and risk of mild cognitive function impairment and dementia amongst people living with cardiovascular diseases: a systematic review protocol

被引:1
作者
Dai, Yunyun [1 ]
Huang, Chongmei [2 ,3 ]
Ding, Jinfeng [2 ,3 ]
Qin, Xiwen [4 ,5 ,6 ,7 ]
机构
[1] Guilin Med Univ, Sch Nursing, Guilin, Peoples R China
[2] Cent South Univ, Xiangya Sch Nursing, Changsha, Hunan, Peoples R China
[3] A JBI Affiliated Grp, Xiangya Ctr Evidence Based Nursing Practice & Hea, Changsha, Hunan, Peoples R China
[4] Univ Western Australia, Sch Populat & Global Hlth, Perth, WA, Australia
[5] Monash Univ, Ctr Med Use & Safety Pharm & Pharmaceut Sci, Melbourne, Vic, Australia
[6] Univ Hong Kong, Dept Pharmacol & Pharm, Fac Med, Hong Kong, Peoples R China
[7] Monash Univ, Victorian Heart Inst, Melbourne, Vic, Australia
关键词
cardiovascular medicines; cognitive function impairment; dementia; meta-analysis; systematic review; RENIN-ANGIOTENSIN SYSTEM; ALZHEIMERS-DISEASE; BLOCKADE USE; METAANALYSIS; DECLINE;
D O I
10.11124/JBIES-20-00257
中图分类号
R19 [保健组织与事业(卫生事业管理)];
学科分类号
摘要
Objective: The objective of this review is to investigate the association between the use of cardiovascular medicines and the risk of mild cognitive function impairment and dementia in people with cardiovascular disease. Introduction: Cardiovascular disease is one of the most important modifiable factors for mild cognitive function impairment and dementia. The current evidence about the effectiveness of cardiovascular disease medicine on the risk of dementia is inconclusive; hence, it is imperative to conduct a comprehensive investigation on the effect of cardiovascular disease medicine on the risk of mild cognitive function impairment and dementia. Inclusion criteria: This review will include studies involving participants (age >= 18 years) who were using cardiovascular medicine for hypertension, myocardial infarction, atrial fibrillation, stroke, or heart failure. The eligible studies will include observational studies and randomized controlled trials. Methods: MEDLINE (Ovid), Embase (Ovid), and PsycINFO (Ovid) will be searched from 2000 to the present. We will only include studies published in English. Titles, abstracts, and full texts will be screened by authors independently. The methodological quality of included studies will be assessed using the JBI critical appraisal checklist for observational studies and randomized controlled trials. The data to be extracted will include the basic study characteristics, populations, drug groups, clinical indicators, and outcomes. Studies will be pooled using statistical meta-analysis, where possible. Alternatively, the findings will be presented in narrative form where statistical pooling is not possible. Systematic review registration number: PROSPERO CRD42020175386
引用
收藏
页码:3142 / 3148
页数:7
相关论文
共 26 条
[1]  
Alzheimer's Disease International, 2019, WORLD ALZHEIMER REPO
[2]  
American Heart Association, 2020, GUID STAT
[3]  
[Anonymous], 2017, DEMENTIA
[4]  
Aromataris E., 2020, JBI Manual for Evidence Synthesis, DOI [DOI 10.46658/JBIMES-20-01, 10.46658/JBIMES-20-01, 10.46658/JBIMES-20-02, DOI 10.46658/JBIMES-20-11]
[5]  
Australian Institute of Health and Welfare, 2017, MED CARD DIS
[6]   The projected effect of risk factor reduction on Alzheimer's disease prevalence [J].
Barnes, Deborah E. ;
Yaffe, Kristine .
LANCET NEUROLOGY, 2011, 10 (09) :819-828
[7]  
British Heart Foundation, 2020, MED HEART CONDITIONS
[8]  
Conant Richard, 2004, Altern Med Rev, V9, P17
[9]  
Dementia Australia, 2020, VASC DEM
[10]   METAANALYSIS IN CLINICAL-TRIALS [J].
DERSIMONIAN, R ;
LAIRD, N .
CONTROLLED CLINICAL TRIALS, 1986, 7 (03) :177-188